目的:了解P-选择素及其配体sLeA、sLeX在食管癌组织及区域淋巴结中的表达,探讨其与食管癌侵袭转移的关系。方法:应用组织芯片技术结合免疫组化检测食管鳞癌86例及其淋巴结P-选择素和sialy lewis A(sLeA)、sialylewis X(sLe X)的表达情况...目的:了解P-选择素及其配体sLeA、sLeX在食管癌组织及区域淋巴结中的表达,探讨其与食管癌侵袭转移的关系。方法:应用组织芯片技术结合免疫组化检测食管鳞癌86例及其淋巴结P-选择素和sialy lewis A(sLeA)、sialylewis X(sLe X)的表达情况,并与16例正常食管鳞状上皮对照。结果:P-选择素在食管癌组织、正常食管鳞状上皮表达率分别为59.3%、12.5%(P<0.05),在转移淋巴结、非转移淋巴结中表达率分别为92.9%、31.3%(P<0.05)。sLeA在食管癌组织,正常食管组织中表达率分别为77.9%、6.25%(P<0.05),在转移淋巴结和非转移淋巴结中表达率分别为97.6%、20.3%(P<0.05)。sLe X食管癌组织、正常食管组织中表达率分别为15.1%、6.25%(P>0.05)。P-选择素和配体sLeA过度表达与食管鳞癌病理分级,TNM分期及淋巴结转移成显著相关性;而配体sLeX在食管癌组织中无过度表达。结论:P-选择素和配体sLeA在食管鳞癌组织、转移淋巴结中表达率明显升高,其与食管癌的侵袭转移有一定关系;配体sLeX与食管癌侵袭转移无关。展开更多
目的探讨大肠腺癌组织粘蛋白MUC2和sialyl lewis X(sLex)的分型与临床各个病理参数之间的关系。方法应用免疫组织化学双染法对34例远切端大肠黏膜、18例大肠腺瘤及55例大肠腺癌组织进行粘蛋白MUC2、sLex检测。结果远切端大肠黏膜、大肠...目的探讨大肠腺癌组织粘蛋白MUC2和sialyl lewis X(sLex)的分型与临床各个病理参数之间的关系。方法应用免疫组织化学双染法对34例远切端大肠黏膜、18例大肠腺瘤及55例大肠腺癌组织进行粘蛋白MUC2、sLex检测。结果远切端大肠黏膜、大肠腺瘤及大肠腺癌中,黏蛋白MUC2阳性表达率分别为100%、94.4%和58.2%(P<0.01);sLex阳性表达率分别为5.9%、50.0%和80.0%(P<0.05)。根据MUC2和sLex在大肠腺癌中的表达把大肠腺癌分为四型:MUC2+/sLex+、MUC2+/sLex-、MUC2-/sLex+、MUC2-/sLex-。MUC2+/sLex+型与患者的性别具有相关性;MUC2+/sLex-型与淋巴结转移、Duke’s分期具有相关性;MUC2-/sLex+型与发生部位、分化程度具有相关性;MUC2-/sLex-型与大肠腺癌临床病理参数均不具有相关性。结论 MUC2的下调表达或sLex的上调表达可能参与了大肠肿瘤的发生及恶性转化,各型大肠腺癌不同程度与其分化、生物学行为相关,对临床上判断预后具有较大的意义。展开更多
The sialyl Lewis X（SLe;） antigen encoded by the FUT7 gene is the ligand of endotheliam-selectin（E-selectin）. The combination of SLe;antigen and E-selectin represents an important way for malignant tumor metastasis...The sialyl Lewis X（SLe;） antigen encoded by the FUT7 gene is the ligand of endotheliam-selectin（E-selectin）. The combination of SLe;antigen and E-selectin represents an important way for malignant tumor metastasis. In the present study, the effect of the SLe;-binding DNA aptamer on the adhesion and metastasis of hepatocellular carcinoma HepG2 cells in vitro was investigated. Reverse transcription-polymerase chain reaction（RT-PCR） and immunofluorescence staining were conducted to detect the expression of FUT7 at both transcriptional and translational levels. The SLe;expression in HepG2 cells treated with different concentrations of SLe;-binding DNA aptamer was detected by flow cytometry. Besides, the adhesion, migration, and invasion of HepG2 cells were measured by cell adhesion assay, and the Transwell migration and invasion assay. The results showed that the FUT7 expression was up-regulated at both mR NA and protein levels in HepG2 cells. SLe;-binding DNA aptamer could significantly decrease the expression of SLe;in HepG2 cells. The cell adhesion assay revealed that the SLe;-binding DNA aptamer could effectively inhibit the interactions between E-selectin and SLe;in the HepG2 cells. Additionally, SLe;-binding DNA aptamers at 20 nmol/L were found to have the similar effect to the monoclonal antibody CSLEX-1. The Transwell migration and invasion assay revealed that the number of penetrating cells on the down-side of Transwell membrane was significantly less in cells treated with 5, 10, 20 nmol/L SLe;-binding DNA aptamer than those in the negative control group（P<0.01）. Our study demonstrated that the SLe;-binding DNA aptamer could significantly inhibit the in vitro adhesion, migration, and invasion of HepG2 cells, suggesting that the SLe;-binding DNA aptamer may be used as a potential molecular targeted drug against metastatic hepatocellular carcinoma.展开更多
文摘目的探讨大肠腺癌组织粘蛋白MUC2和sialyl lewis X(sLex)的分型与临床各个病理参数之间的关系。方法应用免疫组织化学双染法对34例远切端大肠黏膜、18例大肠腺瘤及55例大肠腺癌组织进行粘蛋白MUC2、sLex检测。结果远切端大肠黏膜、大肠腺瘤及大肠腺癌中,黏蛋白MUC2阳性表达率分别为100%、94.4%和58.2%(P<0.01);sLex阳性表达率分别为5.9%、50.0%和80.0%(P<0.05)。根据MUC2和sLex在大肠腺癌中的表达把大肠腺癌分为四型:MUC2+/sLex+、MUC2+/sLex-、MUC2-/sLex+、MUC2-/sLex-。MUC2+/sLex+型与患者的性别具有相关性;MUC2+/sLex-型与淋巴结转移、Duke’s分期具有相关性;MUC2-/sLex+型与发生部位、分化程度具有相关性;MUC2-/sLex-型与大肠腺癌临床病理参数均不具有相关性。结论 MUC2的下调表达或sLex的上调表达可能参与了大肠肿瘤的发生及恶性转化,各型大肠腺癌不同程度与其分化、生物学行为相关,对临床上判断预后具有较大的意义。
基金supported by grants from the National Natural Science Foundation of China(No.81072152)the Natural Science Foundation of Hubei Province(No.2015CFA027)+1 种基金the Research Foundation of Health and Family Planning Commission of Hubei Province(No.WJ2015MA010)the Clinical Medical Research Center of Peritoneal Cancer of Wuhan(No.2015060911020462)
文摘The sialyl Lewis X（SLe;） antigen encoded by the FUT7 gene is the ligand of endotheliam-selectin（E-selectin）. The combination of SLe;antigen and E-selectin represents an important way for malignant tumor metastasis. In the present study, the effect of the SLe;-binding DNA aptamer on the adhesion and metastasis of hepatocellular carcinoma HepG2 cells in vitro was investigated. Reverse transcription-polymerase chain reaction（RT-PCR） and immunofluorescence staining were conducted to detect the expression of FUT7 at both transcriptional and translational levels. The SLe;expression in HepG2 cells treated with different concentrations of SLe;-binding DNA aptamer was detected by flow cytometry. Besides, the adhesion, migration, and invasion of HepG2 cells were measured by cell adhesion assay, and the Transwell migration and invasion assay. The results showed that the FUT7 expression was up-regulated at both mR NA and protein levels in HepG2 cells. SLe;-binding DNA aptamer could significantly decrease the expression of SLe;in HepG2 cells. The cell adhesion assay revealed that the SLe;-binding DNA aptamer could effectively inhibit the interactions between E-selectin and SLe;in the HepG2 cells. Additionally, SLe;-binding DNA aptamers at 20 nmol/L were found to have the similar effect to the monoclonal antibody CSLEX-1. The Transwell migration and invasion assay revealed that the number of penetrating cells on the down-side of Transwell membrane was significantly less in cells treated with 5, 10, 20 nmol/L SLe;-binding DNA aptamer than those in the negative control group（P<0.01）. Our study demonstrated that the SLe;-binding DNA aptamer could significantly inhibit the in vitro adhesion, migration, and invasion of HepG2 cells, suggesting that the SLe;-binding DNA aptamer may be used as a potential molecular targeted drug against metastatic hepatocellular carcinoma.
